GIVE IT UP for Gut Cancer is back!  Give up sugar, booze or the sofa this March and help fund vital research for Kiwis with gut cancers...Sign up for free at www.giveitup.nz.

f
TAGS
H

INTEGRATE Research Trial Update

The INTEGRATE Trial is helping answer an important health question. It has provided evidence that a new treatment, regorafenib, acts against advanced oesophago-gastric cancer and is safe. The investigators are now confident that they can look into a larger trial investigating survival. The trial recruited 152 patients from Australia, New Zealand, Korea and Canada. Patients were randomly allocated to regorafenib or a placebo tablet. Two thirds of the participants were put on the trial drug. All had advanced disease that had come back after chemotherapy. Of the patients taking regorafenib, 46% had no growth in their tumour at 8 weeks, compared with 18% taking placebo. The average overall short term survival was better in the regorafenib.